Page 815«..1020..814815816817..820830..»

Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration – GlobeNewswire

Posted: December 6, 2020 at 2:57 am

BETHESDA, Md. and BALTIMORE, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Gain), today announced a research collaboration with the University of Maryland School of Medicine (UMSOM), to investigate Gains structurally targeted allosteric regulators (STARs) in cellular models of neuronopathic Gaucher disease (nGD) and Parkinsons disease (PD). STARs are proprietary small molecules targeting novel allosteric binding sites on enzymes. These small molecule drug candidates are designed to cross the blood brain barrier and penetrate other hard to treat organs such as bone and cartilage, stabilize the effective enzyme to restore function and reduce toxic substrate. Research will be led by Ricardo A. Feldman, Ph.D., Associate Professor, of Microbiology and Immunology in UMSOM.

Under the terms of the collaboration, UMSOM will investigate Gains STAR candidates in macrophage and neuronal models of nGD and GBA-associated PD. These diseases are characterized by mutations in the GBA gene, where misfolding of the enzyme encoded by GBA (beta-glucocerebrosidase (GCase)) interferes with its normal transport to the lysosome. The research program will aim to further elucidate the mechanism of action of Gains STAR candidates by studying their effect on GCase, including GCases enzyme activity and transport to the lysosome. Additionally, other effects such as prevention of alpha-synuclein aggregation in PD dopaminergic neurons will be evaluated.

We are exceedingly proud to be advancing our work in nGD and Parkinsons in close collaboration with the University of Maryland School of Medicine, said Eric Richman, Chief Executive Officer at Gain. The expertise and experience of UMSOM and Dr. Feldman will be instrumental as we work to further validate the exciting potential of Gains STAR candidate for these devastating diseases. I am confident these foundational studies will bring us closer to a potential new treatment option for those with these disorders.

Dr. Feldman added, Our laboratory has used human induced pluripotent stem cell (iPSC) models of GD and GBA-associated PD to uncover the molecular mechanisms leading to these diseases. We have also developed very sensitive assays to evaluate the therapeutic efficacy of small molecules in reversing the phenotypic abnormalities caused by mutant GBA in the cell types affected by these diseases, including macrophages and neuronal cells. I have been impressed by Gains initial results evaluating the potential of STARs in correcting enzyme misfolding and restoring function, and look forward to working with Gains team to further advance its program to treat these diseases.

Gain and UMSOM intend to report initial data from the collaboration in the first half of 2021.

About Gain Therapeutics, Inc.Gain Therapeutics is redefining drug discovery with its SEE-Tx target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinsons Research (MJFF) and The Silverstein Foundation for Parkinsons with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For more information, visit https://www.gaintherapeutics.com/.

Forward-Looking StatementsAny statements in this release that are not historical facts may be considered to be forward-looking statements. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gains product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gains ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Gain Therapeutics Investor Contact:Daniel FerryLifeSci Advisors+1 617-430-7576daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:Cait Williamson, Ph.D.LifeSci Communications+1 646-751-4366cait@lifescicomms.com

Follow this link:
Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration - GlobeNewswire

Posted in Molecular Medicine | Comments Off on Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration – GlobeNewswire

The COVID-19 vaccine is one of medical researchs greatest achievements – MyBroadband

Posted: December 6, 2020 at 2:57 am

Pfizer and BioNTech recently announced that their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the studys primary efficacy endpoints.

The Phase 3 clinical trial of BNT162b2 began on 27 July 2020 and has enrolled 43,661 participants to date.

Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56 to 85 years of age.

The trial included 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil, and Argentina.

Analysis of the data indicates a vaccine efficacy rate of 95% in participants without prior SARS-CoV-2 infection.

Efficacy was consistent across age, gender, race, and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.

As part of the study 170 cases of COVID-19 were recorded of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group.

There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.

To date, the data monitoring committee for the study has not reported any serious safety concerns related to the vaccine.

The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic, said Pfizer Chairman and CEO Albert Bourla.

Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021.

Professor Eric Topol said the creation of this COVID-19 vaccine will go down in history as one of science and medical researchs greatest achievements perhaps the most impressive.

Topol is the founder and director of the Scripps Research Translational Institute and Professor of Molecular Medicine of Scripps Research.

His view echoes that of Dr Jerome Kim, Director-General of the International Vaccine Institute.

Kim said the speed with which researchers and pharmaceutical companies have responded to the coronavirus epidemic is unprecedented.

He said the medical fraternity is used to five-year time frames, and to see something go into human testing within months is remarkable.

To put the COVID-19 vaccine into perspective, the discovery and research phase for a vaccine usually takes two to five years.

The full process discovery and research, pre-clinical trials, clinical development, regulatory review and approval, and manufacturing and delivery can take more than 10 years.

To condense all the vaccine development phases into less than a year is nothing short of astonishing.

Topol provided a timeline of key milestones to show how several years of work were compressed into months.

Continued here:
The COVID-19 vaccine is one of medical researchs greatest achievements - MyBroadband

Posted in Molecular Medicine | Comments Off on The COVID-19 vaccine is one of medical researchs greatest achievements – MyBroadband

4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development – BioSpace

Posted: December 6, 2020 at 2:57 am

4DMT has made tremendous progress since the close of our Series C financing. We have advanced product candidates across our key therapeutic areas of ophthalmology, cardiology and pulmonology, including the initiation of the clinical programs for 4D-110 and 4D-125 in ophthalmology, and 4D-310 for the treatment of Fabry disease, said David Kirn, M.D., co-founder and chief executive officer of 4DMT. With the addition of Robert Fishman, Raphael Schiffmann and Robert Kim to our clinical R&D leadership team, 4DMT gains not only extensive experience in clinical development and translational medicine, but also unique and specific experience within each of the initial 4DMT therapeutic areas. We are thrilled to welcome these respected leaders to 4DMT.

Dr. Robert Fishman has over 20 years of experience in product development including both medicines and aerosol-based drug/device combinations. Dr. Fishman was most recently Chief Medical Officer at Xoc Pharmaceuticals, where he led Phase 1 development of drugs for prevention of migraine and treatment of Parkinsons disease, and prior to that, at Corcept Pharmaceuticals, a publicly traded biopharmaceutical company. Previously, he was Senior Vice President, Clinical Development, at InterMune (acquired by Roche), where he led the final pivotal trial of pirfenidone (Esbriet) for the treatment of idiopathic pulmonary fibrosis. Before that, at Alexza Pharmaceuticals, he led the Phase 3 studies of inhaled loxapine (ADASUVE), a drug/device combination for the rapid treatment of agitation associated with schizophrenia or bipolar I disorder. Dr. Fishman trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford University pulmonary medicine faculty. He serves as a teaching attending physician in the Stanford pulmonary fellows clinic at Palo Alto Veterans Administration Medical Center, and as an advisor to the Stanford SPARK Program in Translational Research. He received an A.B. in Biology from Harvard University and an M.D. from Stanford University School of Medicine.

Dr. Raphael Schiffmann has over 30 years of experience in clinical research, including as an expert on neurometabolic diseases, focusing his research efforts on lysosomal storage disorders. Dr. Schiffmanns writings include 275 peer-reviewed publications in scholarly journals, and 19 book chapters and reviews. Prior to joining 4DMT, he was the Director of the Institute of Metabolic Disease at the Baylor Research Institute. Before that, Dr. Schiffmann was the lead investigator in the Developmental and Metabolic Neurology Branch at the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH). Dr. Schiffmann has an M.D. degree from the University of Lige, Belgium and a degree of Master of Health Sciences in Clinical Research from Duke University. He is Board Certified in pediatrics and in child neurology and is a Fellow of the American Academy of Neurology.

Dr. Robert Kim has over 20 years of product development experience in ophthalmology. Prior to joining 4DMT, Robert was Chief Medical Officer at Viewpoint Therapeutics, where he led translational development efforts for -crystallin pharmacologic chaperones. Prior to Viewpoint, he was Chief Medical Officer at Apellis Pharmaceuticals and Vision Medicines. Earlier in his career, Robert was Vice President and Head of Pharmaceutical Product Development at Novartis/Alcon and Vice President of Clinical Ophthalmology at GSK. Dr. Kim began his career in drug development at Genentech, where he managed the Lucentis Phase 3 clinical program through to its first product approval in wet age-related macular degeneration. Dr. Kim received his undergraduate and M.D. degrees from Brown University. Dr. Kim completed his residency in ophthalmology at the University of California, San Francisco (UCSF), post-doctoral training in molecular biology at the National Eye Institute, and retina fellowship training at Moorfields Eye Hospital in London before joining the faculty at UCSF. Dr. Kim also holds an M.B.A. from the Haas School of Business at the University of California, Berkeley.

About 4DMT

4DMT is a clinical-stage gene therapy company pioneering the development of product candidates using targeted and evolved AAV vectors. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP, 4D-110 is in a Phase 1 clinical trial for choroideremia and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease.

4D Molecular Therapeutics, 4DMT, Therapeutic Vector Evolution, and the 4DMT logo are trademarks of 4DMT.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005763/en/

See original here:
4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development - BioSpace

Posted in Molecular Medicine | Comments Off on 4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development – BioSpace

Lockdown limits safe spaces for abused women – University of Cape Town News

Posted: December 6, 2020 at 2:56 am

Lockdown has had myriad consequences, including an increase in crimes against women in South Africa and the world. As 16 Days of Activism for No Violence against Women and Children is being commemorated, researchers from the University of Cape Town(UCT) are working collaboratively with national entities invested in the alleviation of this abuse.

The study, Impact of COVID-19 and lockdown on mental health and gender-based violence in South African women, is a collaboration between the Institute of Infectious Disease and Molecular Medicine (IDM) at the UCT Faculty of Health Sciences (FHS), the Centre for the AIDS Programme of Research in South Africa(CAPRISA), the Desmond Tutu Health Foundation(DTHF), the Seattle Childrens Research Institute in the United States and the Burnet Institute in Australia.

At a national address in August, President Cyril Ramaphosa said: As we mark Womens Day this year, South Africa is in the grip of two pandemics the coronavirus pandemic and the scourge of gender-based violence and femicide.

According to the South African Police Service, 87000 cases of gender-based violence (GBV) were reported during the first week of lockdown. The spike in GBV over recent months is attributable to, among other complex contributing factors, the many survivors of violence who were left confined to sharing spaces with their abusers, which often compromise and constrain their access to support services.

MISC

This research is associated with the ongoing clinical study on mucosal injury from sexual contact (MISC) being conducted through a partnership between these research institutes, with Associate Professor Heather Jaspan as co-principal investigator (coPI) and Seattle Childrens Research Institute PI; Associate Professor Jo-Ann Passmore as co-PI and CAPRISA PI; and DrLindi Masson as co-PI and UCT PI. All have appointments through the FHS and are members of the IDM.

The MISC study aims to evaluate the behavioural and biological differences between adolescent and adult South African women in order to understand the extremely high HIV incidence in young women in this country. Among other factors, the study is investigating the impact of the use of vaginal insertion practices and/or sexual trauma on genital inflammation in young women.

The face-to-face clinical activities of this study were halted in March2020, like almost all observational research projects at UCT, following guidance from the UCT Human Research Ethics Committee as a result of the national lockdown. The researchers instead implemented a telephonic survey study to assess the physical and emotional well-being of adolescent and young women living in Philippi, Cape Town, and Vulindlela in rural KwaZulu-Natal.

Economic vulnerability contributes to abuse

Between 2018 and 2019 black African women were recognised as the most economically vulnerable population group in South Africa, with an unemployment rate of over 30%. Many of these women also experienced violence, with almost 50% of assaults committed by someone such as a friend or acquaintance (22%), a spouse or intimate partner (15%), or a relative or other household member (13%). This is according to a Statistics South Africa report.

Concerned that the participants of the MISC study were particularly vulnerable, the researchers sought to offer them support.

A primary goal of the survey was to determine whether any of the study participants were confined in an unsafe environment during lockdown, with the aim of referring them to nearby shelters or social services. At the same time, the United Nations issued a call for data on the impact of COVID-19 on violence against women, and the team recognised the importance of collecting this data locally to contribute to this much larger body of work.

A total of 54 telephonic interviews were conducted during the various stages of lockdown. Of the 28 participants in Philippi, three experienced GBV and/or explicit threats of violence.

One participant was murdered, another verbally threatened by an intoxicated man and the third reported attempted rape. These events highlight the extreme vulnerability of these women and the need for continued support, said Dr Masson.

Ten women in Philippi (36%) and two women in rural KwaZulu-Natal (8%) were scored as having mild depression on the PHQ-9 scale, an evaluation tool with nine questions commonly usedto assess depression.

The study

Masson conceptualised this sub-study, the COVID-19 GBV and depression survey, and implemented it together with project coordinator Celia Mehou-Loko from the FHS, and Dr Hilton Humphries at CAPRISA. They found that concerns surrounding employment, education and the future were the main stressors for most participants.

According to Mehou-Loko, the study consistently considered three essential components: confidentiality, safety and beneficence.

Operating outside the confines of the clinic caused a threat to all three of these key tenets, she said.

Mehou-Loko explained that an additional concern was that participants would be overheard while speaking on the phone with the data collection team, thus potentially compromising their social standing further and putting them in even more danger a consideration which led to the questionnaire being designed to ensure participants could provide simple responses while still allowing for sufficient data collection.

Participants could also send us a Please call me when they felt comfortable, safe and ready to speak freelyIt was also very important that the referral channels, in case of emergency, were tested that the social workers and the NGOs were available to see our participants despite the lockdown, she said.

Evidence to advocate for change

The study highlights some of the unintentional and indirect impacts of lockdown strategies used to mitigate transmission risk in epidemics.

These unintended consequences must be quantified so that in the future more accurate risk and benefit equations can be appreciated ahead of any decisions of this magnitude. In addition, this work may point out opportunities to reduce the risks of violence or better protect women and others, including children, said Professor Linda-Gail Bekker, the chief operating officer at the DTHF and a member of the IDM.

In the future it would be critical to comprehensively evaluate the availability of the support services these young women can access.

The research team intends to use these findings to inform the development of more accurate risk and benefit equations that can be applied before implementing a lockdown in both rural(CAPRISA site) and urban settings(UCT site). This evidence can be used to advocate for continued availability of support services that are critical to ensure the well-being of young women during emergency situations like COVID-19, but also more generally.

Emergency services currently prioritise crisis situations; however, the team has identified a high incidence of lower-grade depression that is important to defuse before it escalates to a more critical point. With simple counselling techniques, follow-up calls and referrals, most participants reporting depression improved their scores to absent or minimal depression, Mehou-Loko said.

Masson echoed this sentiment: In the future it would be critical to comprehensively evaluate the availability of the support services these young women can access and whether these services are adequate.

Crucial in curbing this pandemic is creating awareness about the support services, including the NGOs and hotlines that are available to assist young women. The development of informed campaigns to encourage women to reach out and seek help when they experience emotional difficulties, violence or threats of violence remains key.

Should you need any form of assistance in this regard please call any of these numbers:

Go here to read the rest:
Lockdown limits safe spaces for abused women - University of Cape Town News

Posted in Molecular Medicine | Comments Off on Lockdown limits safe spaces for abused women – University of Cape Town News

The advent of biomimetic apatites in today’s and tomorrow’s medicine – Open Access Government

Posted: December 6, 2020 at 2:56 am

Open Access Government spoke to Prof Christophe Drouet (CNRS Senior Scientist) an international specialist in bio-inspired apatites to learn more about this most absorbing field of research, dealing with regenerative and nanomedicine

Nature has always been a great source of inspiration for humans This is especially true considering biomineralisations as in bones and teeth. By appropriately tuning their composition and conditions of formation in vivo, Nature has designed its own biomaterials, capable of cumulating at once with mechanical strength and bioactivity. Such biominerals are essentially composed of calcium phosphates with an apatite structure, and we have learned over time to master the preparation and processing of synthetic analogues, so-called biomimetic apatites.

This is one focus of our research group in Toulouse. By mimicking crystals naturally present in our bones, these intrinsically biocompatible compounds are particularly well suited to the design of biomaterials for use in vivo: whether in view of bone regeneration or beyond!

In all cases, it is also possible to convey additional functionalities such as anticancer or antimicrobial by exploiting the exceptional surface reactivity of these compounds.

Biomimetic apatites are prepared by soft chemistry, thus avoiding the use of high temperatures to preserve their reactivity and intrinsic features. Indeed, as in natural bone mineral, biomimetic apatite crystals are covered by a hydrated non-apatitic ionic layer which confers to these compounds an exceptionally high surface reactivity, which can be exploited because of biomedical applications. (1) It is then possible provided that the adequate experimental conditions are used to graft on their surface a large variety of bioactive molecules/drugs to set up medical devices.

We have, for instance, shown the possibility to associate antibacterial enzymes, antibiotics, anticancer drugs, hemostatic agents, cell-targeting moieties, anti-osteoporotic drugs, vitamins, and so on to design la carte bioactive compounds. Also, the possibility to modulate their ionic composition allows doping them with bioactive ions which may also play a role in the control of microbial colonisation, inflammation, etc.

Biomimetic apatites are increasingly considered by researchers and clinicians for the design of innovative implantable biomaterials in orthopaedics and dentistry. Using such bio-inspired apatites may indeed ensure not only a high biocompatibility, but also a tailorable resorption rate, which may be modulated via their chemical composition and processing approach. Plus, as mentioned above, several strategies can be developed to confer additional therapeutic functionalities.

Starting in 2004, our group showed for the first time that it was possible to consolidate biomimetic apatite powders into actual 3D scaffolds via cold sintering by a technique called Spark Plasma Sintering (SPS). (2) This opened the way to low-temperature consolidation approaches to preserve the characteristics and performances of such bio-inspired apatites. This low-temperature consolidation is possible by the presence of water molecules on the crystal surface, allowing significant ion mobility.

Lately, this possibility was also extended to amorphous calcium phosphates, often considered as precursors of bone formation in vivo, while preserving again the appealing physicochemical properties of these metastable compounds. (3) We also showed, more recently, that it was possible to coat existing implants (ceramics, metals) such as hip, knee or dental implants with biomimetic apatites so as to significantly increase their bioactivity and osteointegration capacity.

For instance, we proved the relevance of the cold spray technique. Using such reactive apatites is not only a way to boost the biointegration of the implant and allow faster bone repair, but it also allows associating bioactive ions and molecular species, such as antimicrobials to fight or avoid infections. This approach is notably followed in the starting AIMed EU H2020 programme. (4)

Yes indeed. Biomimetic apatites have been developed initially with the idea to propose more efficient bioactive bone substitute materials capable of being functionalised to provide additional effects in vivo, which we showed has great promise. But taking into account their intrinsic biocompatibility, it is also possible to extend the initial usages to a wealth of other medical applications!

In oncology, haematology, dermatology in all such domains where nanomedicine devices are needed, providing small systems to act at the level of cells. (5) It should probably be reminded that nanosized crystals are already present in our bodies since bone is a natural nanocomposite! Here, by designing bio-inspired apatites, we play with nanocrystals that our body can handle and whose biodegradation leads to natural metabolites.

We showed that it was possible to associate, to apatite nanoparticles, a cell targeting agent to address more specifically some diseased cells; that the bio-inspired apatite particle formulation could allow modifying the cellular uptake of some biomolecules/drugs; and that it was possible to design apatite systems for a smart delivery dependent on the body response.

This all opens new avenues of research, typically where an action is needed at a cellular or tissular level. Of course, this requires adapting the formulation and composition to the clinical application, which is why a close contact between materials scientists, galenic pharmacists, clinicians and industrials are needed.

But the role of politicians and decision-makers is also primordial to sustain these developments.

Well, the community now has a strong background on biomimetic/bio-inspired apatites, their elaboration, characterisation, behaviour, processing and properties to certify that these compounds are worth investing further research efforts! However, since the opportunities of use are wide and not yet fully explored by far, additional work is needed in several strategic domains to further ascertain and determine the power of bio-inspired apatites, including in comparison to existing devices often less biocompatible.

Decision-makers could help to promote an active development of biomimetic apatite-based systems by 1) launching dedicated calls for projects at national and European/international scales and providing the necessary funds, 2) setting up a committee of experts about bio-inspired apatites for coordinating research actions, 3) facilitating the development of standards dedicated to such metastable compounds.

In my opinion, this all could allow progressing significantly toward the validation and use of highly-bioactive apatite-based systems in tomorrows medicine for the good of our patientsand the whole healthcare system since these systems are rather low-cost to produce.

(1) Drouet, C. et al. 2018. Nanocrystalline apatites: The fundamental role of water. Am. Miner. 103;550-564.

(2) Grossin, D. et al. 2010. Biomimetic apatite sintered at very low temperature by spark plasma sintering: Physico-chemistry and microstructure aspects. Acta Biomat. 6;577-585.

(3) Luginina et al., First successful stabilization of consolidated amorphous calcium phosphate (ACP) by cold sintering: toward highly-resorbable reactive bioceramics J. Mat. Chem. B, 8 (2020) 629-635.

(4) Horizon 2020 research and innovation programme, Marie Skodowska-Curie grant agreement No 861138, http://www.aimed-itn.eu

(5) Drouet, C. et al. 2020. Colloidal apatite particles: a multifunctional platform in (nano)medicine. Juniper Online J. Mater. Sci. 6 (1);art.555676;1-8.

Member (and PhD supervisor) of the H2020 project AIMed.

*Please note: This is a commercial profile

Editor's Recommended Articles

Originally posted here:
The advent of biomimetic apatites in today's and tomorrow's medicine - Open Access Government

Posted in Molecular Medicine | Comments Off on The advent of biomimetic apatites in today’s and tomorrow’s medicine – Open Access Government

Researchers May Have Found The Gene Responsible For Cellular Aging – Anti Aging News

Posted: December 4, 2020 at 11:54 am

Scientists from the University of Wisconsin Madison believe that they have solved an anti-aging mystery by identifying a gene that is responsible for cellular aging.

Research indicates that cellular reprogramming may be able to reverse the aging that leads to the decline in the activities and functions of mesenchymal stem/stromal cells, but scientists have not been able to figure out which molecular mechanisms are responsible for this reversal.

A study recently published in STEM CELLS may have solved this mystery, enhanced the knowledge of MSC aging and associated disease, and provided insight into developing pharmacological strategies designed to reduce or reverse the aging process.

For this study cellular reprogramming approaches were utilized to establish a genetically identical young and old cell model. While agreeing with previous findings in MSC rejuvenation by cellular reprogramming, our study goes further to provide insight into how reprogrammed MSCs are regulated molecularly to ameliorate the cellular hallmarks of aging, explained lead investigator, Wan-Ju Li, Ph.D., a faculty member in the Department of Orthopedics and Rehabilitation and the Department of Biomedical Engineering.

Cell analysis was conducted to determine if there were any changes in global gene expression resulting from the reprogramming; expression of the protein GATA6 that plays important roles in the gut, lung, and heart development was found to be repressed in the reprogrammed cells as compared to the control cells. Repression of GATA6 led to increased activity of the sonic hedgehog (SHH) protein that is essential to embryonic development as well as the expression levels of FOXp1 proteins required for proper development of the brain, heart and lung.

Thus, we identified the GATA6/SHH/FOXP1 pathway as a key mechanism that regulates MSC aging and rejuvenation, Dr. Li said.

Identification of the GATA6/SHH/FOXP1 pathway in controlling the aging of MSCs is a very important accomplishment. Said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. Premature aging can thwart the ability to expand these promising cells while maintaining function for clinical use, and enhanced knowledge about the pathways that control differentiation and senescence is highly valuable.

In order to determine which of the 4 Yamanaka transcription factors used to reprogram genes to derive iPSCs were involved in repressing GATA6 in the iPSCs, the expression of GATA6 was analyzed in response to the knockdown of each factor. The analysis revealed that only OCT$ and KLF4 were able to regulate GATA6 activity, this finding is consistent with that of several; previous studies.

Overall, we were able to demonstrate that SF-MSCs undergo substantial changes in properties and functions as a result of cellular reprogramming. These changes in iPSC-MSCs collectively indicate amelioration of cell aging. Most significantly, we were able to identify the GATA6/SHH/FOXP1 signalling pathway as an underlying mechanism that controls cell aging-related activities, Dr. Li said.

We believe our findings will help improve the understanding of MSC aging and its significance in regenerative medicine, he concluded.

See original here:
Researchers May Have Found The Gene Responsible For Cellular Aging - Anti Aging News

Posted in Wisconsin Stem Cells | Comments Off on Researchers May Have Found The Gene Responsible For Cellular Aging – Anti Aging News

Osteoporosis treatments could be on the way after scientists identify aging gene – iNews

Posted: December 4, 2020 at 11:54 am

Hopes for new treatments for osteoporosis and cartilage degeneration have been raised after scientists identified a gene that plays a key role in the ageing of bone, tendon, ligament and cartilage.

The researchers hope that they can use their findings to slow down treat age-related diseases connected to the skeletal system by creating treatments that slow down the ageing process behind them.

The i newsletter latest news and analysis

Our findings are novel and significant in finding a critical answer to how skeletal tissues lose their capability to maintain their properties and functions when we age, said Wan-Ju Li, of the University of Wisconsin-Madison.

We can also develop new pharmacological therapies to treat age-associated diseases based on our findings [although] it will take a few years before we can see the application happens, he said.

The study is published in the journal Stem Cells. The journals editor-in-chief, Jan Nolta, of the University of California at Davis, said the discovery is a very important accomplishment.

Researchers said it is possible that the same mechanism that has been identified for the skeletal system may also be present in neural stem cells and cardic stem cells, where it may play a role in causing diseases associated with those areas of the body.

We dont know if the molecule and mechanism we have identified in the paper also play the same role in other stem cells, such as neural stem cells and cardiac stem cells, in causing Parkinsons disease and heart diseases, respectively, since we havent tested it with these cells, Dr Lin said.

But I am sure that other scientists in the fields of aging and brain and heart will follow our study to answer these questions in the future, Dr Lin said.

Go here to read the rest:
Osteoporosis treatments could be on the way after scientists identify aging gene - iNews

Posted in Wisconsin Stem Cells | Comments Off on Osteoporosis treatments could be on the way after scientists identify aging gene – iNews

Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 – Khabar South Asia

Posted: December 4, 2020 at 11:54 am

Stem Cell Assay Market: Snapshot

Stem cell assay refers to the procedure of measuring the potency of antineoplastic drugs, on the basis of their capability of retarding the growth of human tumor cells. The assay consists of qualitative or quantitative analysis or testing of affected tissues andtumors, wherein their toxicity, impurity, and other aspects are studied.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=40

With the growing number of successfulstem cell therapytreatment cases, the global market for stem cell assays will gain substantial momentum. A number of research and development projects are lending a hand to the growth of the market. For instance, the University of Washingtons Institute for Stem Cell and Regenerative Medicine (ISCRM) has attempted to manipulate stem cells to heal eye, kidney, and heart injuries. A number of diseases such as Alzheimers, spinal cord injury, Parkinsons, diabetes, stroke, retinal disease, cancer, rheumatoid arthritis, and neurological diseases can be successfully treated via stem cell therapy. Therefore, stem cell assays will exhibit growing demand.

Another key development in the stem cell assay market is the development of innovative stem cell therapies. In April 2017, for instance, the first participant in an innovative clinical trial at the University of Wisconsin School of Medicine and Public Health was successfully treated with stem cell therapy. CardiAMP, the investigational therapy, has been designed to direct a large dose of the patients own bone-marrow cells to the point of cardiac injury, stimulating the natural healing response of the body.

Newer areas of application in medicine are being explored constantly. Consequently, stem cell assays are likely to play a key role in the formulation of treatments of a number of diseases.

Global Stem Cell Assay Market: Overview

The increasing investment in research and development of novel therapeutics owing to the rising incidence of chronic diseases has led to immense growth in the global stem cell assay market. In the next couple of years, the market is expected to spawn into a multi-billion dollar industry as healthcare sector and governments around the world increase their research spending.

The report analyzes the prevalent opportunities for the markets growth and those that companies should capitalize in the near future to strengthen their position in the market. It presents insights into the growth drivers and lists down the major restraints. Additionally, the report gauges the effect of Porters five forces on the overall stem cell assay market.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=40<ype=S

Global Stem Cell Assay Market: Key Market Segments

For the purpose of the study, the report segments the global stem cell assay market based on various parameters. For instance, in terms of assay type, the market can be segmented into isolation and purification, viability, cell identification, differentiation, proliferation, apoptosis, and function. By kit, the market can be bifurcated into human embryonic stem cell kits and adult stem cell kits. Based on instruments, flow cytometer, cell imaging systems, automated cell counter, and micro electrode arrays could be the key market segments.

In terms of application, the market can be segmented into drug discovery and development, clinical research, and regenerative medicine and therapy. The growth witnessed across the aforementioned application segments will be influenced by the increasing incidence of chronic ailments which will translate into the rising demand for regenerative medicines. Finally, based on end users, research institutes and industry research constitute the key market segments.

The report includes a detailed assessment of the various factors influencing the markets expansion across its key segments. The ones holding the most lucrative prospects are analyzed, and the factors restraining its trajectory across key segments are also discussed at length.

Global Stem Cell Assay Market: Regional Analysis

Regionally, the market is expected to witness heightened demand in the developed countries across Europe and North America. The increasing incidence of chronic ailments and the subsequently expanding patient population are the chief drivers of the stem cell assay market in North America. Besides this, the market is also expected to witness lucrative opportunities in Asia Pacific and Rest of the World.

Global Stem Cell Assay Market: Vendor Landscape

A major inclusion in the report is the detailed assessment of the markets vendor landscape. For the purpose of the study the report therefore profiles some of the leading players having influence on the overall market dynamics. It also conducts SWOT analysis to study the strengths and weaknesses of the companies profiled and identify threats and opportunities that these enterprises are forecast to witness over the course of the reports forecast period.

Some of the most prominent enterprises operating in the global stem cell assay market are Bio-Rad Laboratories, Inc (U.S.), Thermo Fisher Scientific Inc. (U.S.), GE Healthcare (U.K.), Hemogenix Inc. (U.S.), Promega Corporation (U.S.), Bio-Techne Corporation (U.S.), Merck KGaA (Germany), STEMCELL Technologies Inc. (CA), Cell Biolabs, Inc. (U.S.), and Cellular Dynamics International, Inc. (U.S.).

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=40

About Us:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

See the rest here:
Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - Khabar South Asia

Posted in Wisconsin Stem Cells | Comments Off on Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 – Khabar South Asia

From Roaches To Medical Emergencies, Illinois Inmates Say Theres Nobody That We Can Really Go To For Help – WBEZ

Posted: December 4, 2020 at 11:53 am

This article was produced in partnership with the ProPublica Local Reporting Network. Sign up for ProPublicas Big Story newsletter to get stories like this one as soon as they are published.

Randy Liebich curled up in a ball on his bed inside Stateville prison, about an hour outside Chicago. It was June 2010, and hed spent the night in a cold sweat, excruciating pain radiating from his back. For months, hed been filing complaints with prison officials about the lack of medical care. But the forms, known as grievances, got him nowhere.

One was denied, in part because hed already been to the doctor, and the denial noted hed received acetaminophen pain medication. Another complaint was deemed moot.

Now Liebich was in the worst pain of his life. According to medical records, a kidney stone had made it impossible for him to urinate. The men in nearby cells shouted for help.

Correctional officers took Liebich to the medical office, where, records show, a doctor used a hemostat, a tweezer-like surgical tool, to try to remove the stone through the tip of Liebichs penis. But the procedure failed, leaving the stone intact. About six hours passed that day before Liebich was driven to an outside hospital for emergency surgery.

When Liebich got back to the prison, he filed two more grievances about the poor medical treatment hed received. If staff had addressed his earlier complaints, he wrote, he could have avoided the procedure with the hemostat altogether. But prison officials denied those grievances too.

Liebich filed over a dozen more grievances related to his kidney condition over the next eight years, until a judge threw out his murder conviction in 2018 after finding his lawyers ignored key evidence. Prosecutors later dropped all charges, but Liebich says he still suffers trauma from his experience with the hemostat.

People locked inside prisons rely on grievances to complain if their needs, from health care to sanitation to safety, are unmet. The complaints are among their few means of recourse. But in Illinois, that system is sputtering, with little oversight, leaving prisoners vulnerable to harm, an investigation by WBEZ and ProPublica has found.

The state has paid millions to settle the claims of inmates, some of whom raised concerns early through grievances, only to later suffer serious injuries when authorities denied complaints or failed to act.

In one case, a prisoner at Stateville Correctional Center filed a grievance to complain about roaches crawling over him as he slept. He also said he had extreme pain in his ear and heard constant crackling. But he said his complaints were ignored by prison staff. Two weeks after his grievance, records show medical workers removed a bug from his ear. He later filed a lawsuit, alleging ear pain and hearing loss. The case was settled for $12,500, three and a half years after the first grievance. The state denied wrongdoing.

In another case, a man at Stateville spent months filing grievances and writing letters to prison officials about a protruding bolt near his bunk bed. The warden denied the grievances, because theyd been filed as emergencies, and he disagreed with the classification. Eight months after the prisoners initial complaint, he fell out of his bed and hit his eye on the bolt, resulting in disability and disfigurement, according to a lawsuit he filed. Records show he was treated by a doctor the same day. The state disputed the mans claims in court documents, but the parties agreed to a settlement in which the state paid the inmate $70,000.

In Liebichs case, he filed a lawsuit over the medical treatment he received and alleged that prison staff retaliated against him for complaining. The state denied wrongdoing but agreed to a settlement of $70,000.

The Illinois prison system, which had an average daily population of about 40,000 people last year, is now under federal oversight as part of a legal agreement to improve health care in state prisons. A court-appointed expert found in 2018 that the medical care was so poor that people were needlessly dying.

Because grievances can serve as early warnings for prison administrators about dangerous conditions, experts say tracking the complaints is critical.

But WBEZ and ProPublica found Illinois is faltering. The news organizations requested five years of data from the 15 largest prisons, showing the number of grievances and how they were resolved. Only seven were able to provide information that was complete enough to analyze. Some institutions had an entire year of data missing.

Of the grievances that were reviewed by prison officials, about 5% were decided in part, or in whole, in a prisoners favor. Inmates can appeal to a Department of Corrections review board, but the approval rate there was similar, the WBEZ-ProPublica analysis found.

States have different methods of tracking grievances, and its difficult to compare Illinois system to other jurisdictions, but experts said the findings suggest its not working as it should.

With a rate that low, it just seems like nobody believes in the system, said Dan Pacholke, former administrator for the Washington State Department of Corrections and co-author of a book on prison safety. It would certainly be concerning for me as a superintendent of a prison.

Others were more blunt.

What we have here is sort of the fox watching the henhouse, said Jenny Vollen-Katz, executive director of the John Howard Association, an independent citizen group that has monitored Illinois prisons for more than a century.

WBEZ and ProPublica sought an interview with state corrections officials over the course of four months, but the department declined multiple requests. In a written response, it said the approval rate appeared artificially low, in part, because of prolific grievance filers and frivolous complaints. It also noted that many grievances are resolved informally by counselors; about 13% of grievances in the analysis were withdrawn by the inmate before an official review.

Still, in response to a detailed outline of our findings, corrections officials said they were pursuing a number of measures to improve the grievance system, including plans to hire a chief inspector to oversee the statewide system. Officials also said the department would be transitioning to electronic grievances, a move that would make the system more efficient and data easier to track.

The operation of a fair and consistent grievance process is a high priority for the Department, and we are working diligently to improve the current system, the department said in the statement. Through the implementation of significant reforms and an increase in oversight, we can ensure the concerns of men and women in custody are addressed in a timely manner.

Prison watchdog groups and some lawmakers lauded the changes, but they said Illinois system needs a bigger overhaul with more oversight. Some are pushing a proposal to create an ombudsman that would investigate complaints about the department.

Illinois State Rep. La Shawn Ford, a Democrat and former head of the House Restorative Justice Committee, said family members of people in prison regularly call his office asking for help with a grievance. He commended the departments proposed changes but said officials need to make sure that theres a process in place that will allow for the best outcomes for the people making grievances.

You cannot be the judge and the jury and the prosecutor.

In the fall of 1971, nearly 1,300 prisoners took over Attica Correctional Facility in New York to protest abuse and poor living conditions. It was one of the most violent prison standoffs in U.S. history, leaving 43 people dead. Over the next few years, other prison uprisings broke out across the country, as the prison rights movement grew. A report from the U.S. Department of Justice said the lack of grievance systems had probably made these incidents inevitable, because prisoners had no other way to get their needs heard.

Toussaint Losier, a professor of Afro-American studies at the University of Massachusetts-Amherst who has studied American prisons, said grievance systems emerged in this era to create a safety valve to let off some of the steam that could build up over time. But states also had another incentive. Lawsuits filed by prisoners were clogging the federal court system; by 1974, 1 in 20 civil cases filed in federal court were prison civil rights cases, according to Margo Schlanger, a professor of civil rights law at the University of Michigan and a leading expert on prison litigation. Federal judges called for another venue to evaluate complaints. As one put it, if prisoners had a fair alternative, theyd choose that over the delayed process of the courts.

But even after states created grievance systems, the deluge of lawsuits continued. A study from the early 1980s found people incarcerated at two Illinois prisons thought the states grievance system was wholly institution controlled and rarely yielding favorable or even impartial results.

To stem the tide of lawsuits, Congress passed the Prison Litigation Reform Act, or PLRA, in 1996. The legislation made grievances critical by requiring inmates to exhaust the prisons internal grievance system before filing a lawsuit. A co-sponsor of the bill, Sen. Strom Thurmond, R-S.C., said it would prevent frivolous and malicious lawsuits filed by prison inmates. Opponents, including then-Sen. Joe Biden, D-Del., argued the bill unwisely limited the courts power to protect the constitutional rights of people behind bars. The results of the law were striking. The number of lawsuits filed per prisoner shrank by more than 50% over the next two decades, according to Schlanger.

But thats not because prisoners problems were suddenly being addressed through grievances. In fact, some experts say the PLRA may have actually made grievance systems worse. After the law passed, some corrections officials raised administrative hurdles for the complaints, and in doing so made it harder to file lawsuits. Schlanger said prison officials in some states threw out grievances for tiny technical violations, like writing in the wrong color ink.

In Illinois, the state Department of Corrections reduced the window of time within which prisoners can file most grievances from six months to 60 days. It also limited outside oversight of appeals, eliminating a rule that required at least one review board member to come from outside the department. The agency did not respond to a question about the changes.

But officials did note that one reason the approval rate of grievances is so low is because prisoners make technical mistakes, like missing a deadline.

There was a huge incentive to make the grievance process as complicated and as impossible to complete properly as they could, said Alan Mills, a lawyer and executive director of the Uptown Peoples Law Center who has spent decades representing prisoners in Illinois.

Instead of protecting prisoners rights, Mills said grievance systems instead work to protect the department and its employees from lawsuits. In 2011, Mills was part of a team that filed a class-action lawsuit on behalf of deaf and hard of hearing prisoners who werent getting hearing aids or access to interpreters. The plaintiffs argued that they were unable to participate in education programs, stay in contact with loved ones or discuss medical issues with doctors. Mills estimates it took lawyers 18 months to figure out how to exhaust the grievance process so they could move forward with the lawsuit. For example, Mills said, sometimes prison officials would only respond to one issue in a grievance even if a prisoner had listed several issues. This made it unclear if the other issues had been denied, ignored or granted leaving the prisoner unsure if they needed to file additional grievances.

This is 10 extremely qualified, experienced lawyers trying to figure out how to navigate this process. Imagine what somebody who dropped out of sixth grade and is sitting in a jail cell with no resources at all; how they can ever figure out how to make it through that process? Mills said.

The lawsuit later settled with the state agreeing to provide accommodations for deaf and hard of hearing prisoners.

In the spring of 2011, officers at Lincoln Correctional Center ordered about 200 women out of their housing unit. Wielding batons and shields, officers marched the prisoners into a gymnasium and conducted a series of strip-searches, according to a lawsuit the women filed in federal court.

The women were then forced to spread their buttocks and vaginas in view of male staff, and officers made derogatory comments about their bodies, according to the lawsuit. The women, who alleged the search constituted cruel and unusual punishment, also said they were forced to remove tampons and bled on themselves while they waited for others to be searched.

A lawyer for the Department of Corrections denied those claims of mistreatment and said the search was necessary to keep the facility safe from contraband. A jury decided against the prisoners, but the women appealed on different constitutional grounds and that case is ongoing.

Dozens of the women said they filed grievances over the strip-search. But as time passed, many didnt get an answer. Later, the nonprofit John Howard Association conducted a monitoring visit to the prison. According to its report, the group said it heard a significant number of consistent, unsolicited, and independent reports about the strip-search and missing grievances. But the group said that when it asked prison administrators about it, they could not locate a single grievance related to the incident. Nevertheless, the nonprofits report said officials there acknowledged problems with the grievance system and said they made changes to improve tracking.

Maggie Burke, a former state corrections official who retired as warden of Logan Correctional Center in 2017, said grievances routinely disappeared. If it was just an occasional my grievance disappeared, I would think that it was someone who was exaggerating, she said, adding, But it happened a lot.

The problem was so bad that when she became the statewide coordinator for women and family services within the department about two years after the strip-search incident she added locked boxes that only she and her assistant could access. That gave prisoners a direct and more secure way to express concerns or send her grievances.

The system is critical, Burke said, because people may act out violently or create other problems when their grievances arent addressed.

Dwaine Coleman said thats what he did while incarcerated at Vienna Correctional Center in 2014 for marijuana possession. He complained of excruciating back pain, and prison records show he had previously been diagnosed with sciatica. But he said a doctor did little more than tell him to eat well and exercise. So he filed a grievance asking to see another doctor.

A month passed before a corrections counselor wrote that the care Coleman was receiving was appropriate, and the grievance went up the chain of command. Two weeks later, he had yet to get a decision from the warden. Desperate to grab the attention of senior prison officials, Coleman tied his prison-issued bed sheet in knots and began flushing it, bit by bit, down the toilet. The water gushed over the bowl, flooding his cell, according to court records.

The grievance system is a joke. So you kind of have to act out to get your needs met, Coleman said in an interview. When you start to act out, there are incident reports that have to be sent all around, and now theres a paper trail and a lot more people are getting involved.

Coleman said his attempts backfired though and tensions between him and the staff continued to escalate. A few days after the toilet incident, Coleman said he got into an argument with a correctional officer during a medical evaluation, according to a lawsuit he filed. On the way back from the health care unit, Coleman alleged, the officer rammed his head into a doorway. A dental record from about two weeks later shows a chipped tooth. During a civil trial, the officer denied assaulting him. But a jury decided in Colemans favor and awarded him $35,000 in punitive damages.

Coleman did eventually get a decision from the warden on his health care grievance three months after he filed it. The complaint was denied, saying the care he received was appropriate.

Few prisoners in Illinois have faith in the grievance system. Just 5% considered it effective, according to a 2019 survey by the John Howard Association, which collected responses from 12,780 prisoners across the state. And only 13% said they felt comfortable filing a grievance.

The biggest reason that people dont feel comfortable is fear of retaliation, said Vollen-Katz, executive director of the watchdog group.

After Liebich filed grievances complaining about the poor medical care hed received for his kidney stone, he said staff began to view him as a nuisance. In January 2011, officers came to his cell and, according to court records, insisted that he give a urine sample for a drug test.

Liebich told the correctional officers that his kidney condition made that difficult. Officers told him that if he didnt urinate in the next two hours hed be sent to the hole, officially known as segregation. Its a part of the facility where prisoners are sent as punishment, infamous for being filthy, full of bugs and vermin. (In fact, the conditions were so bad that officials shut down that section of the prison in 2016, though it was reopened for COVID-19 quarantining this year.) For Liebich, the pressure to provide a urine sample felt immense. So, with minutes left to his deadline, he asked if he could have more time.

The guards refused and took him to segregation, according to prison records. Because staff knew his trouble with urination, he believes the whole incident was meant to punish him for filing grievances.

Liebichs lawyer sent emails to the warden, letting him know about Liebichs medical condition. But according to records provided by the lawyer, the warden responded that Liebich would need to address his problem through the grievance process.

Five days after the drug test incident, Liebich filed a complaint over being sent to segregation. The officer that reviewed his grievance recommended the warden approve it, according to prison records, but the warden disagreed and Liebich remained in segregation. Still, in August 2011, Liebich pressed forward with a lawsuit alleging poor medical treatment and retaliation. In court documents, prison officials agreed that Liebich was sent to segregation for failure to provide a urine sample, but they denied that officers were acting in retaliation.

The state agreed to a settlement of $70,000 in January 2015, four years after Liebich filed his grievance over his punishment.

Civil rights lawyers, former prison administrators and prisoners say the only way more people behind bars will get their concerns addressed is with independent oversight and increased transparency.

Currently, the entire grievance process is overseen by the Corrections Department.

Grievances first go to a counselor who attempts to resolve the complaint. If they cannot, a grievance officer evaluates the case and makes a recommendation to the warden, who renders a decision. If a prisoner is dissatisfied with the response, they can send their complaint to a statewide board that reviews grievance appeals called the Administrative Review Board.

The whole process can be time consuming.

The state Corrections Department would not say if it had any data showing the speed at which prisons resolved grievances. Records, however, suggest that many complaints were reviewed slowly, or not at all. Over a third of appeals were thrown out because the prisoner had already been released or died by the time the review board evaluated them.

Of those that were reviewed, 7% were found partially or wholly in favor of the prisoner. The panel evaluates thousands of grievances a month. Complaints can range from a missing radio to guard abuse.

When youre seeing that many grievances, its easy to go, Yeah. OK. You know, that one I dont really have time for, said Joni Stahlman, former assistant deputy director of the womens division who sat on the Administrative Review Board in the early 2000s. Theres that tricky line of fairness and getting the work done.

Prison advocates point to a more fundamental issue though: While the four members of the board do not work at any individual prison, they are still employed by the Corrections Department and appointed by the director. Sitting on the current board are two members who previously worked clerical jobs within the department and one who formerly worked inside a prison as a correctional counselor. Vollen-Katz, of the John Howard Association, said thats not true independence. We are asking a closed system to police itself, she said.

Vollen-Katz said one step the state could take would be to create a corrections ombudsman who could investigate complaints and find solutions. Mills, the civil rights lawyer, agreed, saying the Illinois Department of Juvenile Justice already has such a person who gets copies of all the grievances so that they can track them, find trends, figure out problems, and then bring them to the attention of the department to fix.

An ombudsman in the adult system, he said, would be a huge, huge step forward.

In order for it to be effective, though, the position would need complete autonomy, enforcement capabilities and the power to share information with lawmakers and the public, advocates said. Other states, like New Jersey and Washington, already have a corrections ombudsman, and last year Illinois state lawmakers submitted a bill to create one. But the legislation stalled.

Illinois State Rep. Rita Mayfield, who co-sponsored the ombudsman bill, said she planned to revive the legislation next year. She said one of her central motivations was discovering and fixing problems before they become expensive lawsuits.

What can we do to reduce these losses? What is wrong with the system? What can we correct to better utilize those tax dollars? Mayfield said. The Department of Corrections would not answer questions about its stance on an ombudsman.

Losier, the professor who has studied prisons, said another key change to the grievance system should be more transparency. New York state, for example, issues yearly reports on what types of grievances are filed and how the department handles them. That allows the public and lawmakers to monitor whats happening inside. But Illinois issues no such report.

New Yorks Corrections Department also maintains a database that tracks staff involved in misconduct and abuse claims, so the department can look for patterns. But in Illinois, despite records showing staff misconduct is one of the largest issues for prisoners, the department doesnt track grievances by guard name.

Burke, the former warden, said that having that information, even internally, would be helpful. If we have, you know, 90% of our grievances are on one person, then we know that theres a problem there.

Pacholke, the former administrator for the Washington State Department of Corrections, agreed, saying data collection is critical. If youre not tracking it, the next thing you know, something really horrific or tragic can happen, he said.

Neither the Corrections Department nor AFSCME, the union that represents most front-line corrections staff, responded to questions about the potential of tracking complaints about correctional officers.

In Liebichs case, problems within the prison persisted.

In January 2018, after his lawsuit was settled, the staff decided to test him for drugs again, according to discipline records. When he couldnt provide a urine sample, officers sent him back to segregation.

They just went through this with me. They know I have these medical issues, Liebich said in an interview. They know I had a civil suit about it, and they turn around and they did the same thing to me again.

Liebich spent his days in a cramped cell. The prison allowed inmates to leave their cells for mental health groups. Liebich said sessions were held in the former execution area, from when Illinois had the death penalty.

You can literally feel the hairs on your arms and your neck stand up, Liebich said. He felt powerless.

In January 2019, Liebich filed a second lawsuit against the prison over retaliation. Later that year the state agreed to settle and paid him $25,000, but denied wrongdoing.

Today, he said he still has nightmares about his time inside segregation.

Its frightening to think that they can do this to us and get away with it, Liebich said, and theres nobody that we can really go to for help.

WBEZ and ProPublica are investigating oversight in Illinois prisons. Please get in touch with reporter Shannon Heffernan if you have something to share about:

Violence and safety inside Illinois prisons

Staff conduct and oversight

Prisoner discipline

Internal affairs operations

You can reach her via email: sheffernan@wbez.org or phone: 312-893-2937

Shannon Heffernan is a criminal justice reporter for WBEZ. Email Heffernan at sheffernan@wbez.org and follow her on Twitter at @shannon_h.

Claire Perlman and Alex Mierjeski contributed research and Agnel Philip contributed data reporting.

See the rest here:
From Roaches To Medical Emergencies, Illinois Inmates Say Theres Nobody That We Can Really Go To For Help - WBEZ

Posted in Illinois Stem Cells | Comments Off on From Roaches To Medical Emergencies, Illinois Inmates Say Theres Nobody That We Can Really Go To For Help – WBEZ

IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product…

Posted: December 4, 2020 at 11:51 am

NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative allogeneic, autologous and genetically modified gamma-delta T cell therapies for the treatment of cancers (IN8bio or the Company), today announced an upcoming presentation that provides an update of the ongoing Phase I clinical trial of their product candidate INB-100 at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH), which will take place virtually from December 5 to 8, 2020. INB-100 is designed for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation with haploidentical donors.

The poster and accompanying narrated slide presentation is titled, First-in-Human Phase I Trial of Adoptive Immunotherapy with Ex Vivo Expanded and Activated gamma delta T-Cells Following Haploidentical Bone Marrow Transplantation and Post-BMT Cyclophosphamide and reviews the study design and provides a brief update on enrollment and patient status.

The company reported that, as of abstract submission, three female subjects with acute leukemia had been enrolled in the INB-100 Phase 1 trial, of whom two had been dosed, and that no treatment-related adverse events had been recorded. The trial is continuing to enroll and treat patients. The abstract for the presentation can be found at https://ash.confex.com/ash/2020/webprogram/Paper142876.html.

The poster and slide presentation are jointly authored by the scientific and physician investigators from IN8bio and The University of Kansas Cancer Center (KU Cancer Center), and will be presented by the studys Principal Investigator, Dr. Joseph McGuirk, Schutte-Speas Professor of Hematology-Oncology, Division Director of Hematological Malignancies and Cellular Therapeutics and Medical Director, Blood and Marrow Transplant at KU Cancer Center.

This preliminary data report from KU Cancer Center with our allogeneic product candidate, INB-100, demonstrates the absence of significant GvHD in these initial patients, said William Ho, Chief Executive Officer of IN8bio. This suggests that gamma delta T-cells delivered as an off-the-shelf allogeneic cell therapy may be well tolerated and have significant potential to treat patients with serious and life-threatening cancers.

Dr. McGuirk, commented, Potentially curative stem cell transplants using partially matched donors -- called haploidentical transplants have greatly expanded access to stem cell transplantation. The infusion of donor-derived gamma delta T-cells from the stem cell donor, offers the hope of diminishing this risk of relapse and curing more patients.

About IN8bioIN8bio is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. IN8bios technology incorporates drug-resistant immunotherapy (DRI), which has been shown in preclinical studies to function in combination with therapeutic levels of chemotherapy. IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma, which is a difficult to treat brain tumor that progresses rapidly, and INB-100 for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation. For more information about the Company and its programs, visit http://www.IN8bio.com.

Forward Looking StatementsCertain statements herein concerning the Companys future expectations, plans and prospects, including without limitation, the Companys current expectations regarding the curative potential of its product candidates, constitute forward-looking statements. The use of words such as may, might, will, should, expect, plan, anticipate, believe, estimate, project, intend, future, potential, or continue, the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Companys control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Companys current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Companys reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.

Contact:IN8bio, Inc.Kate Rochlin, Ph.D.+1 646.933.5605info@IN8bio.com

Investor Contact:Julia Balanova+ 1 646.378.2936jbalanova@soleburytrout.com

Media Contact:Ryo Imai / Robert Flamm, Ph.D.Burns McClellan, Inc.212-213-0006 ext. 315 / 364Rimai@burnsmc.com/rflamm@burnsmc.com

Go here to see the original:
IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio's Gamma Delta T-cell product...

Posted in Kansas Stem Cells | Comments Off on IN8bio announces first-in-human Phase 1 trial Update from The University of Kansas Cancer Center using INB-100, IN8bio’s Gamma Delta T-cell product…

Page 815«..1020..814815816817..820830..»